Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 2
Submit an article Journal homepage
679
Views
10
CrossRef citations to date
0
Altmetric
Letter to the Editor

Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma

Isabel G. Amslera Department of Medical Oncology, Bern University Hospital, Bern, Switzerland; View further author information
,
Barbara Jekera Department of Medical Oncology, Bern University Hospital, Bern, Switzerland; View further author information
,
Behrouz Mansouri Taleghanib Department of Hematology, University Hospital, Bern, Switzerland; View further author information
,
Ulrike Bacherb Department of Hematology, University Hospital, Bern, Switzerland; View further author information
,
Daniel Betticherc Department of Oncology, Kantonsspital, Fribourg, Switzerland; View further author information
,
Thomas Eggerd Department of Oncology, Kantonsspital, Solothurn, Switzerland; View further author information
,
Thilo Zandere Department of Oncology, Kantonsspital, Lucerne, Switzerland; View further author information
,
Jean-Marc Luethif Department of Medical Oncology, Bern University Hospital, Regionalspital, Thun, SwitzerlandView further author information
,
Urban Novaka Department of Medical Oncology, Bern University Hospital, Bern, Switzerland; View further author information
&
Thomas Pabsta Department of Medical Oncology, Bern University Hospital, Bern, Switzerland; Correspondence[email protected]
View further author information
 show all
Pages 511-514 | Received 09 Dec 2017, Accepted 27 Apr 2018, Published online: 08 Jan 2019
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgments

The authors thank the data management, the apheresis, the flow cytometry, and the stem cell laboratory teams of the ASCT program at the University Hospital of Bern and its associated partner hospitals and collaborators for documentation of data relevant for this study.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http://dx.doi.org/10.1080/10428194.2018.1473577.

Additional information

Funding

This work was supported by a grant of the Swiss Cancer League [SCL #38-167] to TP.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
Source: Elsevier BV
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Source: HAL CCSD
Second primary malignancies in multiple myeloma: An overview and IMWG consensus
Source: Elsevier BV
Lenalidomide and second malignancies in myeloma patients
Source: Elsevier BV

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.